Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD
October 10 2016 - 4:30PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that, on Tuesday, October 11, 2016, prior to the
market open, it will report the results of its Phase IIb
dose-ranging clinical trial of SPN-812 in children for the
treatment of attention deficit hyperactivity disorder (ADHD).
Supernus will hold a conference call with slides on Tuesday,
October 11, 2016, at 9:00 a.m. ET to discuss the topline results of
the clinical trial. The call will be hosted by Jack Khattar,
President and Chief Executive Officer, and Greg Patrick, Vice
President and Chief Financial Officer.
Conference Call Details
Presentation slides will be available via this webcast link. A
question and answer session with the Supernus management team will
follow the company’s remarks.
Please refer to the information below for conference call
dial-in information and webcast registration. Callers should dial
in approximately 10 minutes prior to the start of the call.
Date and
time: |
|
|
Tuesday, October 11,
2016, 9:00 a.m. ET |
Conference
dial-in: |
|
|
(877) 288-1043 |
International
dial-in: |
|
|
(970) 315-0267 |
Conference
ID: |
|
|
93788624 |
Conference Call
Name: |
|
|
Supernus
Pharmaceuticals SPN-812 Phase IIb Topline Results |
Webcast link: |
|
|
Click here |
Following the live call, a replay will be available on the
company's website, www.supernus.com, under ‘Investors’.
About SPN-812
SPN-812 is a selective norepinephrine reuptake inhibitor that
Supernus is developing as a novel non-stimulant for the treatment
of ADHD. The active ingredient in SPN-812, viloxazine
hydrochloride, has an extensive safety record in Europe, where it
was previously marketed for many years as an antidepressant.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in ADHD patients and SPN-812 for
the treatment of ADHD.
Forward-Looking Statements:
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements do not convey historical information, but
relate to predicted or potential future events that are based upon
management's current expectations. These statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. In
addition to the factors mentioned in this press release, such risks
and uncertainties include, but are not limited to, the Company's
ability to sustain and increase its profitability; the Company's
ability to raise sufficient capital to fully implement its
corporate strategy; the implementation of the Company's corporate
strategy; the Company's future financial performance and projected
expenditures; the Company's ability to increase the number of
prescriptions written for each of its products; the Company's
ability to increase its net revenue; the Company's ability to enter
into future collaborations with pharmaceutical companies and
academic institutions or to obtain funding from government
agencies; the Company's product research and development
activities, including the timing and progress of the Company's
clinical trials, and projected expenditures; the Company's ability
to receive, and the timing of any receipt of, regulatory approvals
to develop and commercialize the Company's product candidates; the
Company's ability to protect its intellectual property and operate
its business without infringing upon the intellectual property
rights of others; the Company's expectations regarding federal,
state and foreign regulatory requirements; the therapeutic
benefits, effectiveness and safety of the Company's product
candidates; the accuracy of the Company's estimates of the size and
characteristics of the markets that may be addressed by its product
candidates; the Company's ability to increase its manufacturing
capabilities for its products and product candidates; the Company's
projected markets and growth in markets; the Company's product
formulations and patient needs and potential funding sources; the
Company's staffing needs; and other risk factors set forth from
time to time in the Company's SEC filings made pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934, as amended. The
Company undertakes no obligation to update the information in this
press release to reflect events or circumstances after the date
hereof or to reflect the occurrence of anticipated or unanticipated
events.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024